JP2005532064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532064A5 JP2005532064A5 JP2004519849A JP2004519849A JP2005532064A5 JP 2005532064 A5 JP2005532064 A5 JP 2005532064A5 JP 2004519849 A JP2004519849 A JP 2004519849A JP 2004519849 A JP2004519849 A JP 2004519849A JP 2005532064 A5 JP2005532064 A5 JP 2005532064A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- modified
- polyprotein
- asp
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 189
- 102000004196 processed proteins & peptides Human genes 0.000 claims 188
- 229920001184 polypeptide Polymers 0.000 claims 186
- 108091005804 Peptidases Proteins 0.000 claims 22
- 108010076039 Polyproteins Proteins 0.000 claims 22
- 239000004365 Protease Substances 0.000 claims 22
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 22
- 238000006467 substitution reaction Methods 0.000 claims 21
- 150000001413 amino acids Chemical class 0.000 claims 20
- 108020001507 fusion proteins Proteins 0.000 claims 20
- 102000037865 fusion proteins Human genes 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 6
- 230000024932 T cell mediated immunity Effects 0.000 claims 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39369402P | 2002-07-02 | 2002-07-02 | |
| US39451002P | 2002-07-08 | 2002-07-08 | |
| PCT/US2003/020996 WO2004005473A2 (en) | 2002-07-02 | 2003-07-02 | Hcv fusion proteins with modified ns3 domains |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006174595A Division JP2006265267A (ja) | 2002-07-02 | 2006-06-23 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532064A JP2005532064A (ja) | 2005-10-27 |
| JP2005532064A5 true JP2005532064A5 (enExample) | 2006-08-10 |
Family
ID=30118384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004519849A Pending JP2005532064A (ja) | 2002-07-02 | 2003-07-02 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
| JP2006174595A Pending JP2006265267A (ja) | 2002-07-02 | 2006-06-23 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006174595A Pending JP2006265267A (ja) | 2002-07-02 | 2006-06-23 | 改変したｎｓ３ドメインを有するｈｃｖ融合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1539809A4 (enExample) |
| JP (2) | JP2005532064A (enExample) |
| CN (1) | CN1678630A (enExample) |
| AU (1) | AU2003248818A1 (enExample) |
| CA (1) | CA2491508A1 (enExample) |
| PL (1) | PL374349A1 (enExample) |
| RU (1) | RU2005102484A (enExample) |
| WO (1) | WO2004005473A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491808B2 (en) * | 2000-06-15 | 2009-02-17 | Novartis Vaccines And Diagnostics, Inc. | HCV non-structural protein mutants and uses thereof |
| WO2004039950A2 (en) * | 2002-10-25 | 2004-05-13 | Chiron Corporation | Activation of hcv-specific cells |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| RU2006144714A (ru) * | 2004-05-17 | 2008-06-27 | Чирон Корпорейшн (Us) | Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки |
| ES2377978T3 (es) * | 2004-08-27 | 2012-04-03 | Novartis Vaccines And Diagnostics, Inc. | Mutantes de proteínas no estructurales de VHC y usos de los mismos |
| AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| AU2005295317B2 (en) * | 2004-10-18 | 2011-10-13 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| EP1888751A2 (en) * | 2005-05-25 | 2008-02-20 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
| WO2007041861A1 (en) * | 2005-10-13 | 2007-04-19 | Virexx Medical Corp. | Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response |
| GB0524408D0 (en) * | 2005-11-30 | 2006-01-11 | Glaxosmithkline Biolog Sa | Vaccines |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2061888A2 (en) * | 2006-08-25 | 2009-05-27 | Novartis AG | Hcv fusion polypeptides |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| US9321847B2 (en) | 2010-09-20 | 2016-04-26 | Ramot At Tel Aviv University Ltd. | Activatable toxin complexes comprising a cleavable inhibitory peptide |
| CN107735499B (zh) * | 2015-03-27 | 2022-05-03 | 奥索临床诊断有限公司 | Hcv ns4a/经修饰的ns3多肽及其用途 |
| CN106749672B (zh) * | 2016-11-18 | 2020-06-30 | 江西农业大学 | 一种丙型肝炎病毒融合抗原蛋白及其应用 |
| CN111153963B (zh) * | 2020-01-19 | 2021-08-10 | 华南理工大学 | 抗炎五肽及其提取分离方法和在改善记忆中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239819T3 (es) * | 1993-11-04 | 2005-10-01 | Innogenetics N.V. | Epitopos inmunodominantes de celulas t humanas del virus de la hepatitis c. |
| EP1233982B1 (en) * | 1999-11-24 | 2007-10-24 | Novartis Vaccines and Diagnostics, Inc. | Novel hcv non-structural polypeptide |
| WO2001090812A1 (en) * | 2000-05-23 | 2001-11-29 | Massachusetts Institute Of Technology | Ultraviolet fluoride nonlinear devices |
-
2003
- 2003-07-02 CA CA002491508A patent/CA2491508A1/en not_active Abandoned
- 2003-07-02 EP EP03763172A patent/EP1539809A4/en not_active Withdrawn
- 2003-07-02 WO PCT/US2003/020996 patent/WO2004005473A2/en not_active Ceased
- 2003-07-02 RU RU2005102484/13A patent/RU2005102484A/ru not_active Application Discontinuation
- 2003-07-02 AU AU2003248818A patent/AU2003248818A1/en not_active Abandoned
- 2003-07-02 JP JP2004519849A patent/JP2005532064A/ja active Pending
- 2003-07-02 CN CNA038207192A patent/CN1678630A/zh active Pending
- 2003-07-02 PL PL03374349A patent/PL374349A1/xx not_active Application Discontinuation
-
2006
- 2006-06-23 JP JP2006174595A patent/JP2006265267A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532064A5 (enExample) | ||
| Leary et al. | Sequence and genomic organization of GBV‐C: A novel member of the Flaviviridae associated with human non‐A‐E hepatitis | |
| Muerhoff et al. | Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis | |
| Pizzi et al. | Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. | |
| JP2008516610A5 (enExample) | ||
| Ryan et al. | Virus-encoded proteinases of the Flaviviridae. | |
| RU2005102484A (ru) | Слитые белки hcv c модифицированными доменами ns3 | |
| Kato et al. | Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. | |
| Failla et al. | Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins | |
| CA2390082A1 (en) | Novel hcv non-structural polypeptide | |
| JP2007513634A5 (enExample) | ||
| JP2006518331A5 (enExample) | ||
| JP2016501015A5 (ja) | デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用 | |
| CA2650591C (en) | Methods for the treatment of flavivirus infection, molecules and uses thereof | |
| PL1801209T3 (pl) | Zmodyfikowany genomowy RNA ludzkiego wirusa zapalenia wątroby typu C posiadający zdolność replikacji autonomicznej | |
| JP2006187292A5 (enExample) | ||
| JP2006501825A5 (enExample) | ||
| Ravaggi et al. | Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells | |
| WO2004111082A3 (fr) | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique | |
| JP2016513970A5 (enExample) | ||
| RU2005113692A (ru) | Вакцина против hcv | |
| WO2004048402B1 (en) | A hepatitis c virus codon optimized non-structural ns3/4a fusion gene | |
| JP2008545393A5 (enExample) | ||
| D’Souza et al. | Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro | |
| RU2006144714A (ru) | Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки |